EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells

Nicole R West iD, Mattias F Lindberg, Julien Dairou, Shawn MacGregor, Sahith Puthireddy, Laurent Meijer, Anita Bhattacharyya iD

Disease Models & Mechanisms · 2026

DOI: 10.1242/dmm.052740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2026. Verfasst von Nicole R West und 6 weiteren Autor:innen. Beteiligte Einrichtung: Waisman Center, University of Wisconsin-Madison, Madison, WI, USA. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases, Down Syndrome, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Child Health and Human Development, Bpifrance, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dosage imbalance of dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) is a feature of several neurodevelopmental and neurodegenerative diseases, including Down syndrome, DYRK1A syndrome, autism spectrum disorders, Alzheimer's disease and Parkinson's disease. Thus, manipulating DYRK1A activity in the brain has emerged as a potential therapeutic target for neurological disorders. Several DYRK1A inhibitors have shown promise for improving cognition in rodent models of Down syndrome and Alzheimer's disease, for example, but the ability of these inhibitors to affect DYRK1A levels or activity in relevant human cells has not been established. We filled this gap by testing the effects of a new DYRK1A inhibitor on trisomy 21 induced pluripotent stem cell (iPSC)-derived neural progenitor cells and neurons, in which DYRK1A expression and activity are increased. Our results demonstrated that Leucettinib-21, a potent and selective low-molecular-mass pharmacological inhibitor of DYRK1A, decreases DYRK1A activity in human trisomy 21 iPSC-derived neural progenitor cells and cortical neurons. Leucettinib-21 reduces DYRK1A activity in a relevant human disease model, supporting future human trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesProtein-Tyrosine KinasesDown SyndromeInduced Pluripotent Stem CellsNeural Stem CellsNeuronsGene DosageHumansDyrk KinasesProtein Kinase InhibitorsCell DifferentiationDioxolesImidazoles

Stichwörter der Autor:innen

Cell proliferationDYRK1ADYRK1A inhibitorsDown syndromeInduced pluripotent stem cellsTau phosphorylation

Substanzen

Dyrk KinasesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProtein Kinase Inhibitors((5Z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4H-imidazol-4-one)DioxolesImidazoles

Autor:innen und Institutionen

  • Waisman Center, University of Wisconsin-Madison, Madison, WI, USA.
  • Cellular and Molecular Biology Graduate Program, University of Wisconsin-Madison, Madison WI 53706, USA.
  • Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France.
  • Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris Cité, Paris 75270, France.
  • Department of Cell and Regenerative Biology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.

ORCID-Profile: Nicole R West, Anita Bhattacharyya

Förderung

  • National Institute of Child Health and Human Development
  • Bpifrance
  • NICHD NIH HHS
  • HORIZON EUROPE European Innovation Council
  • Agence Nationale de la Recherche
  • School of Medicine and Public Health, University of Wisconsin-Madison
  • Fondation Jérôme Lejeune
  • Wisconsin Alumni Research Foundation

Zitieren

APA

West, N. R., Lindberg, M. F., Dairou, J., MacGregor, S., Puthireddy, S., Meijer, L., & Bhattacharyya, A. (2026). Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052740

Vancouver

West NR, Lindberg MF, Dairou J, MacGregor S, Puthireddy S, Meijer L, et al. Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells. Disease Models & Mechanisms. 2026. doi:10.1242/dmm.052740

BibTeX
@article{West2026,
  author = {West, Nicole R and Lindberg, Mattias F and Dairou, Julien and MacGregor, Shawn and Puthireddy, Sahith and Meijer, Laurent and Bhattacharyya, Anita},
  title = {Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells},
  journal = {Disease Models & Mechanisms},
  year = {2026},
  doi = {10.1242/dmm.052740}
}
Kostenlos starten →